AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02014909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
Study NCT01754805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study NCT01754805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral
Study NCT03958045 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rucaparib and Nivolumab
Description: Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
Study NCT00905437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as an adjunct to standard of care
Study NCT00905437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 75 mg BD for 14 days
Study NCT03799445 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03799445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03799445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03799445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03799445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02120690 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Trigeminal nerve stimulation
Description: 10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
Study NCT02120690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal nerve stimulation
Description: 10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
Study NCT04637373 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
Study NCT04554355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based PA intervention
Description: Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
Study NCT02687815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 4000 IU
Description: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
Study NCT02687815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
Study NCT02384031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traumatic needle
Description: Lumbar puncture is performed with a traumatic needle
Study NCT02384031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic needle
Description: Lumbar puncture is performed with an atraumatic needle
Study NCT04149366 — intervention group
Intervention type: DEVICE
Intervention: Retainer
Description: Orthodontic retainer
Study NCT02137473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human milk-based fortifier
Study NCT02137473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bovine protein-based fortifier
Study NCT00452127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO131921
Description: Escalating doses by IV infusion
Study NCT02777554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast IR
Description: Apremilast immediate release tablet
Study NCT03343769 — intervention group
Intervention type: OTHER
Intervention: Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements
Description: 3 10-second repetitions
Study NCT00376168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plant cell expressed recombinant glucocerebrosidase (prGCD)
Description: Intravenous infusion every two weeks for 9 months
Study NCT00376168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plant cell expressed recombinant glucocerebrosidase (prGCD)
Description: Intravenous infusion every 2 weeks for 9 months
Study NCT03863613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pessary
Description: A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.
Study NCT03863613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage using Mc Donald technique, under anaesthesia
Study NCT03863613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
Study NCT03854903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib is taken orally.
Study NCT03854903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is given as an intramuscular injection.
Study NCT00515060 — intervention group
Intervention type: OTHER
Intervention: Sensory Tests
Description: Tests to find the threshold at which perceive stimuli.
Study NCT01585597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoll- Coolgaurd 3000
Description: Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
Study NCT03376919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLs++ gait training
Description: CLs++ gait training
Study NCT02397512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: application of lactulose
Description: Subjects will ingest 50g of lactulose once
Study NCT02397512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: application of sucrose
Description: Subjects will ingest 50g of sucrose once
Study NCT01960257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System
Description: This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
Study NCT01960257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC DOT
Study NCT03035188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
Study NCT02777554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast XL
Description: Apremilast extended release formulation tablet
Study NCT02890173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Study NCT02890173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Study NCT00868920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient control of pump
Description: Patient controls sedation pump during colonoscopy.
Study NCT00868920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anesthesiologist controlled sedation
Description: Anesthesiologist will control the sedation pump during colonoscopy.
Study NCT03028428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placenta Derived Mesenchymal Stem Cell
Description: 1ml 1\*10\^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
Study NCT03028428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate administered into the knee joint once
Study NCT03981172 — intervention group
Intervention type: BEHAVIORAL
Intervention: Daily snack food intake
Description: participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
Study NCT03160378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational skills training
Description: 10 sessions of parent and child training in a group format.
Study NCT03160378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual in the outpatient clinic
Study NCT03160378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual in the outpatient clinic
Study NCT02000492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Football
Study NCT02000492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Running
Study NCT02000492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit training
Study NCT01813617 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive Agents
Description: Patients in the cohort received medical treatment according to standard care.
Study NCT03218020 — intervention group
Intervention type: OTHER
Intervention: No intervention assigned, this is an observational study.
Description: No intervention assigned, this is an observational study.
Study NCT03842319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiota analysis
Description: From the feces and oral cavity samples, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
Study NCT03842319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunological analysis
Description: A study of immunological cell populations, inmunogenetics and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
Study NCT03842319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proteome analysis
Description: A study of host and microbiota proteome will be carried out from samples using mass spectrometry
Study NCT03842319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolome analysis
Description: A study of host and microbiota metabolome will be carried out from samples using MS-based as well as NMR-based methods
Study NCT03842319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Description: Clinical evaluation including hemostasis and biochemical studies
Study NCT03842319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet evaluation
Description: Biochemical analysis and questionaries for diet adherence and exercise registration
Study NCT03842319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedDiet
Description: The high-intensity Mediterranean diet will include the promotion of the following: a) abundant use of olive oil (>40 g/d) for cooking and dressing dishes; b) consumption of >2 daily servings of vegetables; c) >2-3 daily serving of fresh fruits; d) >3 weekly servings of legumes; e) >3 weekly servings of fish or seafood; f) >1 weekly serving of nuts or seeds; g) select white meats instead of red meats or processed meats; and h) cook regularly with tomato, garlic and onion adding or no other aromatic herbs, and dress vegetables, pasta, rice and other dishes with tomato, garlic and onion adding or no other aromatic herbs. Two main meals per day should be eaten (seated at a table, lasting more than 20 minutes). A recommendation to drink a glass of wine per day during meals is given. Limited consumption is advised for cured ham, red meat, chocolate, cured or fatty cheeses
Study NCT01965860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional curriculum (E-learning + simulation)
Study NCT01965860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional E-learning
Study NCT04525534 — intervention group
Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment
Study NCT02657486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Study NCT02502032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different groups received different pretreatments of cisatracurium.
Study NCT00204490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isoflavones
Description: soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
Study NCT00204490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate
Description: carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
Study NCT01880866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (-)-Epicatechin
Description: A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
Study NCT03252405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mask ventilation
Description: before intravenous induction, mask application is made. then intravenous cannulation and induction
Study NCT03252405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous cannulation
Description: induction is applied by using intravenous cannulation
Study NCT03252405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous cannulation
Description: induction is applied by using intravenous cannulation
Study NCT05117216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Vigilant Care (Parental training)
Study NCT05117216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Vigilant Care (Parental training)
Study NCT05117216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technological Parental Monitoring
Study NCT04800081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.
Study NCT04800081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.
Study NCT03334435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT03334435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baricitinib
Description: Administered orally
Study NCT03334435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03334435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03566628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed Isotonic Saline
Description: Isotonic saline warmed to 39ºC.
Study NCT03566628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Room-Temperature Isotonic Saline
Description: Isotonic saline at room temperature
Study NCT01857063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
Study NCT01857063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
Study NCT02131480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m²
Study NCT02131480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 1,1 mg/m²
Study NCT02132585 — intervention group
Intervention type: PROCEDURE
Intervention: Speckle tracking echocardiography
Study NCT01528241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP688
Description: Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
Study NCT04705285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbium Yag Laser
Description: Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month
Study NCT04705285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Training
Description: Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
Study NCT01871363 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: * radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.
Study NCT03151759 — intervention group
Intervention type: RADIATION
Intervention: Neoadjuvant radiotherapy
Description: Neoadjuvant radiotherapy prior to rectal cancer surgery
Study NCT00938275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5g SRT2104
Description: SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment.
Study NCT02472600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Study NCT02472600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin
Study NCT02472600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
Study NCT02472600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
Study NCT04259398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
Study NCT04259398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane is administered for induction and maintenance of anesthesia
Study NCT02516462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVM media
Description: Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
Study NCT02516462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Description: Low dose FSH is administered to stimulate follicle growth.
Study NCT04472910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Folforinox (mFFX)
Description: Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
Study NCT00540982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: 0.5 mg/kg will be administered by IV push to determine clearance
Study NCT00540982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 1 mg/kg will be administered to determine metabolic capacity
Study NCT01916447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.